Drug intelligence / Profile preview

HLBP-038

Development stage: Preclinical
Lead developer: HLB Pharma
Modality: Peptides
Administration: Subcutaneous

Overview

HLBP-038 is a long-acting injectable formulation of the GLP-1 receptor agonist semaglutide, developed by HLB Pharma for the treatment of obesity and diabetes. The drug utilizes HLB Pharma's proprietary SMEB (Smart Microsphere Emulsion Bead) technology, a sustained-release microsphere platform designed to provide stable drug concentrations over an extended period. This formulation aims to improve patient compliance by reducing the frequency of administration to once a month, compared to the weekly dosing required for standard semaglutide injections. HLBP-038 is currently in the preclinical stage of development.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on HLBP-038.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLBP-038.

Explore the full profile